EndoStim

About EndoStim

EndoStim, a medical device company established in 2009, is headquartered in St. Louis, Missouri, with additional operations in Nijmegen, Netherlands. The company was founded by a team that includes Bevil J. Hogg, who brought his experience from the medical device sector, having previously co-founded and managed other ventures in the field. The venture originated from a collaboration between Hogg and a group of surgeons and inventors, including Dr. Virender K. Sharma, who conceived of the initial idea of using electrical stimulation for the lower esophageal sphincter. EndoStim is focused on addressing gastroesophageal reflux disease (GERD), a condition affecting a significant portion of the global population where the valve between the esophagus and stomach malfunctions, causing acid to flow back. The company has developed a neurostimulation therapy designed for patients with severe GERD who do not respond well to standard pharmaceutical treatments like proton pump inhibitors (PPIs). This treatment, known as LES stimulation, involves the minimally invasive implantation of a small, pacemaker-like device. The device delivers low-energy electrical pulses to the lower esophageal sphincter (LES), the muscle that acts as a barrier between the stomach and the esophagus. By strengthening and restoring the function of this muscle, the therapy aims to prevent stomach acid from refluxing into the esophagus, thereby addressing the root cause of the disease rather than just managing its symptoms. The system is programmed and controlled by physicians to meet the specific needs of each patient. EndoStim's business model revolves around the sale of this proprietary medical device to hospitals and surgical centers. Its target market consists of gastroenterologists and upper GI surgeons who treat patients with chronic and severe forms of GERD. The company has secured regulatory approvals in various international markets, including CE Marking in Europe and approvals in several Latin American countries, allowing it to commercialize its product outside the United States. As of early 2025, the device is still under investigation in the U.S. and is limited by federal law to investigational use within the country, pending FDA approval.